The adjustment in price target by a major bank like Deutsche Bank reflects a nuanced view on 10x Genomics' valuation, suggesting a positive outlook albeit with a slightly reduced growth expectation. This could lead to mixed short-term reactions in the market, balancing between the continued endorsement via a Buy rating and the lowered price target.